ILCs include natural killer (NK) cells and three other main subsets, ILC1, ILC2 and ILC3, referred as to helper-like ILCs [@R1], [@R2], [@R3]. Since their discovery, ILCs have been shown to contribute to wound healing and defense against infection, and recent studies have revealed critical aspects of their differentiation. However, much of the role of ILCs remains to be elucidated, particularly given the diversity of these cells, which adds to the complexity of their analysis.

Unlike T and B cells, ILCs do not express antigen-specific receptors derived from RAG-dependent gene rearrangements. Other than this major difference in their recognition repertoire, the ILC and T-cell subsets display striking similarities, as ILC1, ILC2 and ILC3 are driven by the T-bet, GATA-3 and RORγt transcription factors, and produce the cytokines IFN-γ, IL-5/IL-13 and IL-17/IL-22, respectively [@R1], [@R2], [@R3]. In addition, NK cells are driven by Eomes and T-bet, can be cytolytic and produce IFN-γ, like CD8^+^ T cells. This similarity of features led to suggestions that ILCs are the innate counterparts of T cells [@R1], [@R2], [@R3]. During the course of evolution, two highly parallel systems have thus emerged, with ILCs mimicking the effector profile of T cell subsets. However, it remains unclear how these two systems are integrated by the innate and adaptive immune systems in natural conditions in humans.

In mice, all ILCs are generated by an Id2-dependent pathway from a common lymphoid progenitor (CLP), which initially differentiates into a common ILC precursor (CILP). CILPs differentiate into three precursors, giving rise to three different lineages: NK-cell precursors (NKPs), lymphoid tissue--inducer precursors (LTiPs), and common helper innate lymphoid precursors (CHILPs). CHILPs express the PLZF transcription factor and give rise to the ILC1, ILC2, and ILC3 subsets. LTi cells are essential for the development of secondary lymphoid organs, such as lymph nodes and Peyer's patches in mice. By contrast, ILC differentiation in humans is poorly understood [@R4]. For instance, the human counterparts of CILP and CHILP have yet to be described and much remains to be understood about ILC differentiation. NK cell progenitors with a Lin^−^CD34^+^CD38^+^CD123^−^CD45RA^+^CD7^+^CD10^+^CD127^−^ phenotype have been found in bone marrow, cord blood and tonsils [@R5]. These cells differentiate exclusively into NK cells and are unable to generate ILC2, ILC3 and other lineages. ILC3 progenitors have been identified in human tonsils and intestinal lamina propria, but not in bone marrow, thymus or peripheral blood [@R6]. A Lin^−^CD34^+^CD45RA^+^CD117^+^IL-1R1^+^RORγt^+^ progenitor population that expressed ID2 gave rise *in vitro* to all ILCs, including NK cells, but not to other leukocyte lineages. This RORγt^+^ progenitor was selectively found in tonsils, lymph nodes, and spleen, but not in peripheral blood, bone marrow, umbilical cord blood, or thymus [@R7].

Severe combined immunodeficiency (SCID) is a life-threatening condition that affects infants and is characterized by defective T cell development associated with various deficiencies of other cell lineages, such as NK, B and myeloid cells [@R8], [@R9]. Patients present with profound abnormalities in immunity, leading to severe recurrent and fatal infections. The life-threatening nature of SCID requires treatment by allogeneic hematopoietic stem cell transplantation (HSCT) or gene therapy to resolve the immune deficiency syndrome [@R9], [@R10], [@R11]. HSCT most often requires a conditioning regimen in the patients to induce myeloablation, and hence favors engraftment. Some SCID patients carry mutations of the *IL2RG* gene (which encodes the γc cytokine receptor subunit SCIDX1) or autosomal-recessive mutations of *JAK3*. Both these types of mutation result in a complete block of T and NK cell development [@R12]. We dissected here the differentiation and function of human ILCs, by analyzing these cells in patients with SCID resulting from *IL2RG* and *JAK3* mutations, before and after treatment by allogeneic HSCT. We found that SCID patients with *IL2RG* and *JAK3* mutations were ILC-deficient and continued to display ILC deficiency after HSCT in the absence of myeloablation. No particular susceptibility to disease was observed in these patients. Together with earlier findings for mice [@R13], [@R14], these results provide evidence for possible redundancy of the protective immune function of ILCs in the presence of a functional adaptive immune system.

Results {#S1}
=======

Circulating ILCs in healthy children and adults {#S2}
-----------------------------------------------

ILC1, ILC2 and ILC3 are mostly present as sedentary cells in tissues, in which they can be maintained by self-renewal [@R15]. Nevertheless, cells from these ILC subsets are detectable in human peripheral blood [@R16], [@R17], [@R18]. Using a panel of conventional lineage markers (Lin: CD3, CD19, CD14, TCRαβ, TCRγδ, CD94, CD16, FcεRI, CD34, CD123, CD303) and the cell surface expression of CD127, CD117 and CRTH2, we identified ILC1 as Lin^−^CD127^+^CD117^−^CRTH2^−^, ILC2 as Lin^−^CD127^+^CRTH2^+^ and ILC3 as Lin^−^CD127^+^CD117^+^CRTH2^−^ cells among the circulating lymphocytes. NK cells were classically defined as CD3^−^CD56^+^ lymphocytes ([Fig. 1a](#F1){ref-type="fig"}). All ILC subsets were detected in the peripheral blood of healthy children (6 -- 18 years) and adults. NK cells were by far the most abundant circulating ILCs (median of 215 × 10^3^ cells/ml and 265 × 10^3^ cells/ml in healthy children and adults, respectively), and total ILC counts were only 3.8 × 10^3^ cells/ml and 1.6 × 10^3^ cells/ml in healthy children and adults, respectively ([Fig. 1b,c](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The counts and percentages of helper-like ILCs in peripheral blood lymphocytes decreased with age ([Fig. 1b](#F1){ref-type="fig"}), whereas this trend was not observed for NK cells ([Fig. 1c](#F1){ref-type="fig"}). We also investigated whether there was any association between the counts of circulating ILC1 vs ILC2 vs ILC3 in healthy patients, and whether there was an impact of gender on these values. In accordance with the common origin of helper-like ILCs, there was a strong positive correlation between the absolute numbers of ILC2 and ILC3 in children and adults, and weak or moderate positive relationship for ILC1 and other ILCs ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). There was however no difference in gender (data not shown). Consistent with the higher counts of ILCs in children, ILCs were elevated in umbilical cord blood as compared to both children and adult values ([Fig. 1d](#F1){ref-type="fig"}). Circulating ILC1, ILC2 and ILC3 displayed equivalent percentages of total helper-like ILCs and this distribution remained stable across age groups ([Fig. 1e](#F1){ref-type="fig"}). Together, these results establish normal values for human circulating ILCs under natural conditions which are consistent with those reported previously for adults [@R19], and they pave the way for comparisons with data of circulating ILCs for patients with various pathological conditions.

Absence of circulating ILCs in T^−^B^+^NK^−^ SCID patients {#S3}
----------------------------------------------------------

ILC1, ILC2 and ILC3 are IL-7-dependent, whereas NK cells are dependent on IL-15 [@R20]. The IL-7 and IL-15 signals are integrated via the common γc cytokine receptor subunit and the downstream JAK3 protein tyrosine kinase. NK cell deficiency is a known hallmark of typical cases of SCIDX1 and JAK3 deficiencies [@R12]. We therefore analyzed the presence of other ILCs in SCID patients presenting genetic deficiencies of this pathway. Our cohort comprised 28 SCID patients (12 *IL2RG-,* 9 *JAK3-* and 7 *RAG*-deficient) and 6 control patients ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, [Table 2](#SD2){ref-type="supplementary-material"}). Among these 28 SCID patients, circulating ILCs could be monitored prior to HSCT in 5 patients and post-HSCT in 20 patients ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, [Table 2](#SD2){ref-type="supplementary-material"}). No circulating ILCs were detected in the peripheral blood of three of the SCID patients (P19, P20 and P21) with *JAK3* deficiency prior to HSCT ([Fig. 2](#F2){ref-type="fig"}). These data are consistent with the absence of tonsils and palpable lymph nodes [@R8], [@R21], [@R22], suggesting the absence of the LTi subset of ILCs in patients with this condition. In contrast, the ILC compartment was phenotypically normal in patients (C11 and C12) with *RAG1*-deficiency ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}), consistent with the lack of requirement for *RAG*-dependent DNA recombination events in the development of ILCs in the mouse [@R2], [@R3], [@R23], [@R24], [@R25].

ILC deficiency in non-myeloablative HSCT-treated SCID {#S4}
-----------------------------------------------------

We then analyzed the reconstitution of ILCs in 18 T^−^B^+^NK^−^ SCID patients who had undergone HSCT, 7 to 39 years before the ILC analysis, with mild myeloablation or no myeloablation in all but one (P4) ([Table 2](#T2){ref-type="table"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). This cohort consisted of 7 children (P1 to P7) and 11 adults (P8 to P18) with *IL2RG* (12 patients) or *JAK3* mutations (6 patients). We also analyzed circulating or tissue-resident ILCs in 6 SCID patients with *RAG1* or *RAG2* mutations selectively impairing T and B cell development, who underwent HSCT after myeloablation (C1, C2, C9, C10, C11, C13). T cell reconstitution was observed in both groups of patients ([Fig. 3a,b](#F3){ref-type="fig"}) [@R26]. In almost all SCID patients of the first group who did not undergo myeloablative HSCT, analysis revealed a highly specific split chimerism, with the T cells of donor origin, whereas the other leukocyte subsets were of host origin ([Table 2](#T2){ref-type="table"}) [@R27]. In the SCID patients with *RAG1* mutations, long-term analysis revealed complete donor chimerism, providing evidence of donor HSC engraftment ([Table 2](#T2){ref-type="table"}). ILC2 and ILC3 were barely detectable in the peripheral blood of both pediatric ([Fig. 3a](#F3){ref-type="fig"}) and adult ([Fig. 3b](#F3){ref-type="fig"}) patients with SCID and *IL2RG* or *JAK3* mutations undergoing HSCT. Consistent with previous reports, circulating NK cells were either undetectable or present at only very low numbers in all of these patients ([Fig. 3a,b](#F3){ref-type="fig"}). Similarly, ILC1 were generally undetectable, but low ILC1 counts were obtained for a fraction of children and adults ([Fig. 3a,b](#F3){ref-type="fig"}). However, high ILC1 counts were obtained for one child who was otherwise healthy (P1) and one adult with chronic lung infections (P12) ([Fig. 3a,b](#F3){ref-type="fig"}). Human ILC1s are highly heterogeneous, and data indicate that ILC1s include cells synthesizing transcripts encoding variable regions of the T-cell antigen receptor [@R28], [@R29], and other molecules typically expressed by T cells, such as CD4, CD5, CD6, CD28 and CD27 [@R29], [@R30]. Indeed, most of the ILC1 in HSCT-treated SCID patients and healthy controls were CD5^+^ ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). These results suggest that a substantial fraction of ILC1 may belong to the T-cell lineage and that the number of true ILC1 reconstituted in HSCT-treated SCID patients may be even lower than that estimated by classical Lin^−^CD127^+^CD117^−^CRTH2^−^ cell-surface phenotype analysis. Nevertheless, our results show that SCID patients with *IL2RG* and *JAK3* mutations continue to display ILC deficiency after HSCT in the absence of myeloablation.

One obvious limitation of the above analysis was the lack of data on tissue-resident ILCs. Skin and gut paraffin-embedded and frozen tissue sections were obtained from 6 *IL2RG* or *JAK3* SCID patients treated with non-myeloablative HSCT (P1, P3, P5, P11, P14, P16) ([Table 2](#T2){ref-type="table"}). With the exception of P3, these biopsies were performed at a distance from the HSCT (1 to 10 years). In these samples, the presence of all NKp46^+^ subsets of ILCs was assessed i.e. NK cells [@R2], tissue-resident CD127^−^ILC1 ([@R31]) and NCR^+^ILC3 ([@R2]), on the basis of positive staining for NKp46 and an absence of CD3 expression. This analysis was made possible via the generation of a monoclonal antibody screened for its reactivity against paraffin-embedded tissues. In these tissues, NKp46^+^ ILCs were not detected or barely detectable as shown in 3 representative *IL2RG* or *JAK3* SCID patients treated with non-myeloablative HSCT ([Fig. 4a](#F4){ref-type="fig"}). Frozen sections of gut biopsies from two patients (P1 and P3) were also analyzed. In a representative patient, P3, T cells (CD3^+^) were detected, but no cell--associated NKp46 staining was detectable, in sharp contrast to the results obtained for controls ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}).

We also sought to also analyze ILC2 in tissue sections corresponding to the samples assessed for NKp46^+^ ILCs. However, the consensus marker of ILC2, CRTH2, cannot be used in tissue sections. An alternative involved reliance on immunofluoresence stainings based on the CD3^−^CD11b^−^ICOS^+^ST2^+^ or Lin^−^CD34^−^ST2^+^IL-17RB^+^KLRG1^+^ phenotype as described earlier [@R32]. However, the density of expression of ST2 varies with ILC2 activation [@R33], and thus does not seem as reliable as the CRTH2 staining used to identify circulating ILC2s. We thus used the CD3^−^CD11b^−^ICOS^+^ phenotype to evaluate the presence of ILC2s in gut and skin. In these tissues, ILC2s were barely detectable as shown in 2 representative *IL2RG* or *JAK3* SCID patients treated with non-myeloablative HSCT ([Fig. 4d](#F4){ref-type="fig"}). Similar conclusions were drawn using the Lin^−^CD34^−^KLRG1^+^ staining (data not shown).

The specificity of our staining protocols was confirmed by the absence of detectable staining in tissues of two aplastic *RAG1* SCID patients (C11 and C13) obtained 3 months after failure of HSCT performed in myeloablative conditions ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Thus, SCID patients with *IL2RG* and *JAK3* mutations were deficient in circulating and likely tissue-resident ILCs, and this deficiency persisted after non-myeloblative HSCT.

ILC reconstitution in myeloablative HSCT {#S5}
----------------------------------------

A question that can be raised from the above results is whether ILC reconstitution may no longer happen in post-natal life in patients with *IL2RG-* or *JAK3*-deficiency. Only one *IL2RG* SCID patient investigated in this study underwent myeloablative HSCT (P4) ([Table 2](#T2){ref-type="table"}). ILC reconstitution was not observed in P4 peripheral blood ([Fig. 3a](#F3){ref-type="fig"}), indicating that, if myeloablation is one of the factors involved in the reconstitution of circulating ILCs in HSCT-treated SCID patients, it is not the only parameter. However, partial tissue-resident ILC reconstitution was observed in patients treated with HSCT under mild myeloablative conditions, as shown in the representative P15 patient out of the 3 patients examined sharing similar HSCT settings ([Fig. 4c](#F4){ref-type="fig"}). We also analyzed the long-term (\> 4 years) reconstitution of all subsets of circulating ILCs in patients undergoing myeloablative HSCT for leukemia (ALL, n = 3 or AML, n = 1), aplastic anemia (n = 2) or SCID with *RAG1* mutations (n = 2). All these patients displayed complete donor chimerism (CDC, [Table 2](#T2){ref-type="table"}). In these settings, NK cells, ILC1, ILC2 and ILC3 were detected ([Fig. 3](#F3){ref-type="fig"}). The counts of these cells in blood were heterogeneous, particularly for ILC1 ([Fig. 3a,b](#F3){ref-type="fig"}). For ILC2 and ILC3, cell counts in the blood were lower than those of age-matched controls for pediatric patients ([Fig. 3a](#F3){ref-type="fig"}), but were normal (ILC2) or close to normal (ILC3) in adults ([Fig. 3b](#F3){ref-type="fig"}). As expected, complete NK cell reconstitution was observed in pediatric and adult patients ([Fig. 3a,b](#F3){ref-type="fig"}). The long-term reconstitution of circulating ILCs after HSCT was thus observed in these myeloablative conditions. In addition, NKp46^+^ ILCs and ILC2 were readily observed in skin and gut tissues from 2 representative *RAG*-deficient patients (C9 and C10) treated with myeloablative HSCT ([Fig. 4b,d](#F4){ref-type="fig"}). Thus, ILCs can be reconstituted postnatally. Therefore, ILC reconstitution can occur in humans after the transplantation of allogeneic hematopoietic grafts, but these cells develop only in myeloablative conditions. Our data also show that the precursors of all ILC subsets are present in human bone marrow and cord blood, the two sources of hematopoietic cells used for HSCT for the SCID patients included in our cohort ([Table 2](#T2){ref-type="table"}).

ILC reconstitution in mouse HSCT {#S6}
--------------------------------

To further ascertain the lack of tissue-infiltrating ILCs in HSCT-treated patients, we used mouse models to mimic HSCT in myeloablative and non-myeloablative conditions. CD45.2^+^ bone marrow LSK (Lin^−^Sca1^+^cKit^+^) progenitors were sorted as both Flt3^int^ multipotent progenitors (MPP) and as Flt3^+^ lymphoid-primed multipotent progenitors (LMPP) ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}), and injected into sub-lethally irradiated or non-irradiated alymphoid CD45.1^+^ *Rag2*^−/−^*Il2rg*^−/−^mice. Three weeks post-HSCT, ILC populations from liver, lungs and intestine in recipient mice were analyzed. Lung ILC2 (Lin^−^Gata3^+^CD127^+^ICOS^+^ST2^+^) populations were observed in all irradiated mice but undetectable in all non-irradiated mice ([Fig. 5](#F5){ref-type="fig"}, [Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). Similarly, intestinal ILC2 (Lin^−^CD127^+^Gata3^+^KLRG1^+^), and intestinal NCR^+^ILC3 (Lin^−^Thy1^+^CD127^+^NKp46^+^RORγt^+^), NCR^−^ILC3 (Lin^−^Thy1^+^CD127^+^CD4^−^NKp46^−^RORγt^+^) and LTi-like ILC3 (Lin^−^Thy1^+^CD127^+^CD4^+^NKp46^−^RORγt^+^), were reconstituted in the intestinal lamina propria in irradiated *Rag2*^−/−^*Il2rg*^−/−^ recipient mice, but barely detectable in non-irradiated mice ([Fig. 5](#F5){ref-type="fig"}, [Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). Thus, ILC2 and ILC3 reconstitution was effective in all sub-lethally irradiated recipients but not in non-irradiated recipient mice. For ILC1 and NK, the reconstitution was much more effective than for ILC2 and ILC3 in non-myeloablative conditions, as intestinal lamina propria ILC1 (Lin^−^NKp46^+^NK1.1^+^CD49a^+^CD49b^−^) and NK cells (Lin^−^NKp46^+^NK1.1^+^CD49a^−^CD49b^+^) of donor origin were equally present in both irradiated and non-irradiated *Rag2*^−/−^*Il2rg*^−/−^ recipient mice ([Fig. 5](#F5){ref-type="fig"}, [Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). Although liver ILC1 (Lin^−^NKp46^+^NK1.1^+^CD49a^+^CD49b^−^) were detected in irradiated *Rag2*^−/−^*Il2rg*^−/−^ recipient mice, they were reduced in non-myeloablative conditions ([Fig. 5](#F5){ref-type="fig"}, [Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"}). Similarly, lung NK cells (Lin^−^NKp46^+^NK1.1^+^CD127^+^) can be reconstituted in non-myeloablative conditions, but not as efficiently as in irradiated *Rag2*^−/−^*Il2rg*^−/−^ recipient mice ([Fig. 5](#F5){ref-type="fig"}, [Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). Nonetheless, circulating NK cells (Lin^−^NKp46^+^NK1.1^+^CD49a^−^CD49b^+^) were detected in *Rag2*^−/−^*Il2rg*^−/−^ recipient mice reconstituted in non-myeloablative conditions (data not shown), indicating the sampling of ILCs is correlated to the presence or absence of tissue-resident ILCs. The absence of ILC2 and ILC3 chimerism in non-myeloablative conditions in mice support the data from HSCT-treated SCID patients and suggest the inability of CHILPs in humans and in mice to fully differentiate into appropriate niches as they might compete with endogenous progenitors in these niches. This mechanism of donor HSC engraftment restriction by occupancy of niches by host HSCs is supported by the data showing that the clearance of HSC niches via antibody treatment leads to efficient transplantation [@R34].

Human ILC deficiency is not associated with disease {#S7}
---------------------------------------------------

In HSCT-treated SCID patients, we observed no increase in non-conventional T-cell subsets, such as γδ T cells or Vα24^+^Vβ11^+^ NKT cells that could compensate for the absence of ILCs on the basis of similarities in effector function ([Supplementary Fig. 7a, b](#SD1){ref-type="supplementary-material"}). The almost total absence of ILCs in these patients thus provided us with a highly informative situation for evaluating the function of ILCs in natural conditions in humans. Remarkably, this situation of persistent ILC deficiency had no major clinical consequences over very long periods of follow-up (7 to 39 years) ([Table 3](#T3){ref-type="table"}). This cohort of patients was no more prone to infection or inflammation than those undergoing HSCT for other types of SCID with or without myeloablation [@R26], [@R35]. Growth and quality of life were similar in these groups of patients. A higher than normal incidence of human papillomavirus (HPV) infections, leading to chronic HPV disease, has been observed in HSCT-treated SCID patients with *IL2RG* or *JAK3* mutations [@R36]. However, no association was detected between HPV infection and the absence of NK cells [@R36] or other ILCs (this study), consistent with the notion that HPV infections are controlled by IL-2Rγc or JAK-3-dependent signaling in keratinocytes rather than in lymphocytes [@R37], [@R38]. Nine *IL2RG* or *JAK3* SCID patients from the cohort required immunoglobulin substitution because of residual B cell deficiency due to impaired IL-21R and IL-4R signaling in *IL2RG*- or *JAK3*-deficient B cells [@R39] ([Table 3](#T3){ref-type="table"}). The pattern of ILC detection in the blood was similar for these patients and for the other patients of the cohort. ILCs thus appear to be dispensable in humans with a functional adaptive immune system, demonstrating redundancy between ILCs and adaptive lymphocytes in humans in natural conditions.

Discussion {#S8}
==========

We aimed here to contribute to the understanding of ILC differentiation and function in humans in natural conditions. We focused our analysis on a cohort of T^−^B^+^NK^−^ SCID patients with *JAK3* or *IL2RG* deficiencies, and showed that these patients lacked all ILC subsets. These results are consistent with the strict dependence of ILC1, ILC2, ILC3 and NK cells on IL-7 or IL-15 [@R40], [@R41], [@R42].

The *JAK3* or *IL2RG* SCID patients of our cohort underwent allogeneic HSCT, which could be performed in the absence of myeloablation due to the absence of allogeneic immune responses in the recipients. In these HSCT protocols, split chimerism was generally observed, with the development of T cells from the transplanted donor cells, and the other lineages remaining of host origin [@R27]. Progenitor T cells are thought to persist in the long term in the absence of donor HSC engraftment [@R27], [@R43]. In this setting, no reconstitution of blood NK, ILC2 and ILC3 was observed. In tissues, a marked reduction of NKp46^+^ ILCs and ILC2 was also observed. Thus, SCID patients with *IL2RG* and *JAK3* mutations continued to display ILC deficiency after HSCT in the absence of myeloablation. However, was a trend for a better reconstitution of ILC1 that can even expand in a few patients (2 out of 18 in our study). Among all ILC subsets, ILC1 are still ill-defined. In particular, it is possible that some of these ILC1 might correspond to activated T cells with low expression of the CD3-TCR complex. The cell surface expression of CD5, but also CD4, CD28, CD3 molecules and TCR transcript is consistent with this hypothesis [@R28], [@R29], [@R30]. The lack of a robust consensual definition of ILC1 phenotype is most likely one of the factor leading to the apparent heterogeneity of ILC1.

By contrast, circulating and tissue ILCs were detected in most patients of our cohort who underwent HSCT with myeloablation, consistent with earlier reports showing an early wave of NK cells [@R44], and slow incomplete ILC reconstitution in these settings [@R16]. The partial nature of the reconstitution of circulating ILCs in these patients makes it impossible to rule out the possibility of ILC precursors or differentiated ILCs seeding various anatomical sites throughout the body during embryonic development, with subsequent maintenance by self-renewal *in situ*, contributing to the production of tissue-infiltrating ILCs after birth [@R15], [@R45]. In this hypothesis, ILCs could have 2 distinct anatomical and temporal origins: during embryonic life from organs to be identified, and from bone marrow after birth and upon stress conditions, like HSCT. This dual ILC system would parallel the observation of the layered system composed of tissue-resident macrophages originating mainly from yolk sac progenitor cells and of macrophages originating from bone marrow hematopoietic stem cells [@R46]. Nevertheless, our data indicate that ILCs can be reconstituted postnatally. These data are supported by similar results obtained in our mouse model of HSCT.

ILCs are seen as sentinels and local guardians of tissue functions, and many immune functions have been attributed to them, mostly based on experimental challenges in mice or *in vitro* experiments with human cells [@R1]. However, the small number of genes selectively expressed by ILCs or ILC subsets [@R28] and the consequent lack of mouse models selectively targeting ILC subsets has hindered attempts to dissect the selective contribution of these cells to immune defenses *in vivo* [@R47]. The drastic reduction of all subsets of circulating and tissue-resident ILCs in transplanted *IL2RG* and *JAK3* SCID patients, at the exception of rare cases of ILC1 reconstitution, provided an informative model to assess the role of ILCs in natural conditions in humans. It is clear from our study that major ILC deficiencies appear to be clinically silent, strongly contrasting with the severe clinical conditions associated with T and B cell deficiencies. Thus ILCs appear redundant at least in the context of modern medicine and hygiene, providing an alternative view of their immune function. Further very long-term evaluation, beyond 40 years, will nevertheless be required to determine whether T cell, NK cell and ILC redundancy is maintained in older patients. Our findings are supported by the redundancy between ILC3 and T cells in protection against *Citrobacter rodentium* intestinal infections in mice [@R13], [@R14]. They are also consistent with case reports of impaired NK cell effector function without apparent clinical immunodeficiency in humans [@R48]. Noteworthy, NK cells have been shown to contribute to tumor immune-surveillance, and our cohort is too small for addressing this possibility. Given the similarities between ILCs and T cells in terms of transcription factor expression, cytokine secretion and localization, ILCs are probably substituted by T cells rather than by B cells. Redundant mechanisms ensuring a robust immune response may have led to the selection of the features common to ILCs and T cells. Our data, indicating that ILCs are part of a multi-layered protective arsenal of immune cells, suggest that it would be useful to dissect the role of ILCs in patients with various genetic or acquired conditions compromising adaptive immunity, including patients on immunosuppressive treatments. The depletion of circulating ILCs has recently been reported in HIV-infected patients not receiving early antiretroviral therapy, but the impact of this lack of ILCs on immunodeficiency and the underlying mechanisms remain unknown [@R19]. Further investigations of the role of ILCs in these conditions, and during embryonic life, early childhood and old age, will be essential to provide a full understanding of ILC biology.

ILCs have also been shown to play a role in reproduction. Indeed, the uterine ILC population, including NK cells, expands during pregnancy, and these cells have been reported to regulate placental development and fetal growth in humans and mice [@R49]. However, two female *JAK3*-deficient patients included in our study had no signs of fertility disorders, and had healthy babies with a normal birth weight and no other pathological symptoms following clinical event-free pregnancies. ILCs therefore appear to be dispensable for human reproduction in natural conditions.

Methods {#S9}
=======

Patients and healthy control individuals {#S10}
----------------------------------------

Patients were treated by allogeneic HSCT in the Immuno-Hematology Department of Necker Children's Hospital (Paris, France) or in the Pediatric Hematology and Oncology Department of Timone Enfants Hospital (Marseille, France). The cells transplanted were obtained from mismatched related donors (MMRD, 19 patients), phenotypically matched related donors (PRD, 5 patients), unrelated umbilical cord blood (UUCB, 4 patients), matched unrelated donors (MUD, 1 patient) or matched sibling donors (MSD, 3 patients). The characteristics of the patient and the HSCT are provided in [Table 2](#T2){ref-type="table"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Clinical events and the personal variables of the patients were assessed retrospectively, with data collected during annual visits to the outpatient clinic. All clinical events present two years after HSCT or occurring thereafter were recorded, together with the timing, severity, and outcome of these events. Chimerism was determined on total blood or sorted cell lineages, by XY-fluorescence *in situ* hybridization (FISH) or by the polymerase chain reaction amplification of short tandem repeats. For each cell lineage, mixed chimerism was defined as the presence of 10% to 90% donor-derived cells. Blood samples were obtained with consent from patients or families in the context of routine follow-up. In order to minimize variability, exclusion criteria were established. Thus, healthy controls had no infections or current diseases (e.g. hematological, systemic, cardiac, renal). All children were admitted to the Department of Pediatric Surgery of the Timone Hospital (Marseille) during programmed hospitalizations before minor surgery procedure as undescended testes, circumcision or frenulum surgery. These healthy controls were referred to the outpatient clinics of Conception Hospital (Marseille) for diagnostic blood testing. They underwent routine blood testing before minor elective surgery. Cord blood were collected from siblings of patients treated for hematological malignancies. When these cord blood units were not compatible with the recipient, parents and guardians have signed an informed consent for studies on these samples before destruction. This study was performed according French rules (Art. L. 1243-1 et Art. L. 1245-2 du Code de la Santé Publique). All patients gave written informed consent for participation, including possible inclusion in genetic studies, and the study was approved by the local ethics committee of the Hôpital Necker (Paris) and the Hôpital de la Timone (Marseille). The characteristics of the patients, including age and sex, are presented in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Cell preparation and flow cytometry {#S11}
-----------------------------------

Human blood samples were centrifuged on a Ficoll gradient to obtain a preparation enriched in peripheral blood mononuclear cells (PBMCs), which was then frozen, as previously described [@R50]. T and B lymphocytes were quantified with 6-Color BD Multitest and BD Trucount technologies, according to the manufacturer's instructions (Becton Dickinson, San Diego, USA). The monoclonal antibodies (mAbs) used to analyze human cells are provided in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}. Data were acquired with a FACSCanto II cytometer (T/B/NK subsets) or a Fortessa X20 cytometer (helper-like ILC subsets), both from Becton Dickinson. Data were analyzed with FlowJo software.

Immunofluorescence and immunohistochemistry on tissue sections {#S12}
--------------------------------------------------------------

Human intestine and skin biopsy specimens were isolated from HSCT-treated SCID patients with *IL2RG* or *JAK3* mutations and control individuals. For immunofluorescence, samples were thoroughly washed in PBS and embedded in optimum cutting temperature compound, frozen in a bath of isopentane cooled on dry ice, and cut into 8 μm-thick sections. Before staining, sections were fixed by incubation in cold acetone for 10 minutes before saturation. Human NKp46 staining was then performed with a polyclonal goat anti-human NKp46 antibody (R&D Systems, France), followed by an Alexa488-conjugated donkey anti-goat secondary antibody (Molecular Probes, France). Human CD3ε staining was performed with a mouse anti-human Alexa647-conjugated mAb (BD Pharmingen, France). DAPI (Invitrogen, France) was used to counterstain the nucleus. After staining, the slides were allowed to dry and mounted in Prolong Gold (Invitrogen, France) for examination under a Leica SP5 confocal microscope (Leica). Images were processed with Leica LAS Lite and Adobe Photoshop software. For ILC2 immunohistochemistry, paraffin embedded sections of gut and skin biopsy samples from patients and controls were incubated with rabbit anti-KLRG1 (Biorbyt, Cambridge, UK), mouse anti-CD3 (Abcam, Cambridge, UK), rat anti-CD11b (R&D Systems, Minneapolis, USA) and Pacific Blue-labeled anti-lineage markers (Lin; CD3, CD14, CD16, CD19, CD20 and CD56) (Biolegend, London, UK). The following secondary antibodies were used: Dylight-conjugated chicken anti-rat 350 (Agrisera-AB, Vännäs, Sweden), Alexa-Fluor-labeled donkey anti-goat 594, -goat anti-rabbit 660, -donkey anti-mouse 647 (Life Technologies, Darmstadt, Germany) and donkey anti-rabbit 488 (Abcam). Toluidine Blue staining was performed according to standard protocols using a working solution with a pH between 2.0 and 2.5. Six randomly chosen high-power fields at 200-fold magnification per patient or healthy volunteer were evaluated by two experienced researchers in a blinded manner. For NKp46^+^ ILC immunohistochemistry, paraffin embedded sections of gut and skin biopsy samples from patients and controls were double stained automatically with Leica Bond Max autostainer (Leica Biosystem). Antibody used were polyclonal anti-CD3 (DAKO) and anti-NKp46 (clone 8E5B Innate Pharma, Marseille, France). A full characterization of the 8E5B mAb will be published elsewhere.

Reconstitution experiments in mice {#S13}
----------------------------------

All mice were C57/BL6/J females used between 6 and 9 week old. *Rag2*^−/−^*Il2rg*^−/−^ mice bearing the CD45.1 allele were used as recipients in the reconstitution experiments. CD45.2^+^ hematopoietic progenitors from the bone marrow of C57BL/6 congenic mice were sorted and injected intravenously in the retro-orbital sinus of sub-lethally irradiated (500 rad, cesium source) or non-irradiated *Rag2*^−/−^*Il2rg*^−/−^ recipient mice. CD45.2^+^Lin^−^Sca1^+^cKit^+^Flt3^med^ (MPP) and Lin^−^Sca1^+^cKit^+^Flt3^hi^ (LMPP) cells were mixed for the bone marrow grafts transplanted into sub-lethally irradiated and non-irradiated CD45.1^+^ *Rag2*^−/−^*Il2rg*^−/−^ host mice. Recipients received 7 × 10^3^ adult hematopoietic progenitors and reconstitution was analyzed three weeks after transplantation. The recipient livers, lungs and intestines (lamina propria and intra-epithelial lymphocytes) were analyzed by flow cytometry for the presence of donor (CD45.2^+^) or recipient (CD45.1^+^) lymphoid cell populations.

Statistical analysis {#S14}
--------------------

Statistical analyses were performed with Prism 5 (GraphPad Software, San Diego, CA).

Supplementary Material {#SM}
======================

The authors thank all patients and their families for participating in the study, C. Bonnafous, N. Anceriz (Innate-Pharma) for the anti-NKp46 mAbs, F. Suarez (Paris), N. Schleinitz (Marseille) and Y. Bertrand (Lyon) for enrolling patients in the study, and the Laboratory of Hematology (P.E. Morange, Marseille) for sample storage. The E.V. laboratory is supported by the European Research Council (THINK Advanced Grant), the *Ligue Nationale contre le Cancer (Equipe Labellisée*) and by institutional grants from INSERM, CNRS and Aix-Marseille University to CIML. E.V. is a scholar of the *Institut Universitaire de France*. The A.F. laboratory is supported by the European Research Council (Pidimmune Advanced Grant), by institutional grants from INSERM, Paris Descartes University, *Collège de France* and an *Investissements d'Avenir* IHU grant. The R.G. group is supported by institutional grants from Institut Pasteur, INSERM, Université Paris Diderot and the Agence Nationale de la Recherche (Grant "Myeloten"), the Institut National du Cancer and an USPC grant "Mucocell".

**Author contributions**

V.B., B.V. and B.N designed the research, performed experiments and analyzed the data; C. Piperouglou, J.B., N.Y., F. T., T.P., M.P., J.D., A.R. and R. G. performed the experiments and analyzed the data; N. M., N. Z., C. F., G. M., D.M., S.B., H.S., A.D. and C. Picard. provided key expertise, reagents or samples. F.V., A.F. and E.V. devised and supervised the study, designed the research, and wrote the manuscript, with the help of the other co-authors.

**Competing financial interests**

E.V. is the cofounder of and a shareholder in Innate Pharma. The other authors have no conflicting financial interest to declare.

![Normal ILC levels in the peripheral blood of healthy pediatric and adult controls\
**(a)** Flow cytometric analysis of ILCs in healthy human peripheral blood (PB). ILCs are defined within the CD45^+^ lymphocyte gate as Lin^−^CD127^+^ cells, with a lineage cocktail containing antibodies directed against CD3, CD19, CD14, TCRαβ, TCRγδ, CD94, CD16, FcεRI, CD34, CD123, and CD303. (**b)** ILC1, ILC2 and ILC3 counts in healthy children (blue, n = 29) and adults (orange, n = 30). Absolute numbers are indicated in numbers of cells per milliliter of peripheral blood. (**c**) NK cell counts in healthy children (blue, n = 29) and adults (orange, n = 30). NK cells are defined as CD3^−^CD56^+^ within the CD45^+^ lymphocyte gate. Absolute numbers of cells per microliter of peripheral blood are indicated. Distribution of ILC1, ILC2 and ILC3 within lymphocytes (**d**) or helper-like ILCs (**e**), is shown for cord blood (black), healthy children (blue) and healthy adults (orange). The subset distribution within the lymphocyte gate is represented in percentages. Medians, 10^th^ and 90^th^ percentiles are shown in box-plots. Outliers are indicated as dots. Data are from one experiment representative of more than 60 independent experiments with similar results (**a**), 29 and 30 experiments (**b,c,d**) or 7 experiments (**e**). NS, not significant (P \> 0.05). \* P=0.01 by Mann-Whitney test.](emss-69497-f001){#F1}

![Severe ILC lymphopenia in *JAK3* SCID patients\
ILCs are defined within the CD45^+^ lymphocyte gate as Lin^−^CD127^+^ cells. Comparative ILC staining is shown for (**a**) 3 representative *JAK3* SCID patients (P19, P20, P21) and (**b**) 2 *RAG1* SCID patients (C11, C12) before HSCT are shown as controls.](emss-69497-f002){#F2}

![Long-term ILC lymphopenia in HSCT-treated SCID patients\
Absolute numbers (cells/µl) are indicated for CD3^+^ T cells, CD19^+^ B cells and CD3^−^CD56^+^ NK cells in the peripheral blood. Absolute numbers (cells/ml) are indicated for ILC subsets in the peripheral blood. (**a**) Black circles correspond to 6- to 14 year-old healthy controls (HC, n = 12), individual colors represent individual patients and correspond to 6- to 14 year-old *IL2RG* or *JAK3* SCID patients (n = 7) and colored triangles correspond to control patients with complete donor chimerism (CDC, n = 5). **(b)** Healthy adult controls (HC, n = 26), adult *IL2RG* or *JAK3* SCID patients (n = 11) and control patients with complete donor chimerism (CDC, n = 3) are shown as black squares, colored squares and colored triangles, respectively. NS, not significant (P \> 0.05). \* P=0.05 by Mann-Whitney test.](emss-69497-f003){#F3}

![Absence of intestinal and skin ILCs in HSCT-treated SCID patients\
CD3^−^NKp46^+^ and CD3^−^CD11b^−^ICOS^+^ staining was used to identify tissue-resident NKp46^+^ ILCs and ILC2 respectively in indicated organs. (**a**) left, duodenum sample from P5 (*IL2RG*) 10 years post non-myeloablative HSCT; middle, skin sample from P11 (*JAK3*) 18 years post non-myeloablative HSCT; right, colon from P16 (*IL2RG*) 5.5 years post non-myeloablative HSCT. (**b**) left, duodenum sample from C9 (*RAG1*) 15 months post-myeloablative HSCT; middle, skin sample from C10 (*RAG2*), 4 months post-myeloablative HSCT; right, colon sample from C9. (**c**) duodenum sample from P15 (*IL2RG*) 15 months post-myeloablative HSCT. (**d**) colon sample from P5, skin sample from P11, colon sample from C9 and skin sample from C10. Scale bar, 50 μm.](emss-69497-f004){#F4}

![Reconstitution of ILCs after engraftment of adult multipotent progenitors into *Rag2^−/−^Il2rg^−/−^* deficient mice\
Indicated ILC subsets from the lungs, liver and small intestine (SI) were analyzed by flow cytometry after the reconstitution of irradiated and non-irradiated CD45.1^+^ *Rag2^−/−^Il2rg^−/−^* recipient mice with multipotent progenitors sorted from CD45.2^+^ C57BL/6/J adult bone marrow. By using CD45.1 and CD45.2 congenic markers, donor-derived (CD45.2^+^) hematopoietic populations were separated from their recipient (CD45.1^+^) counterparts. ILC1 and NK cells from the lungs were identified as NKp46^+^NK1.1^+^IL7Rα^+^ and NKp46^+^NK1.1^+^IL7Rα^−^ respectively. ILC2 from the lungs were identified as Lin^−^Gata3^+^IL7Rα^+^ cells co-expressing ICOS and ST2. The expression of CD49a and CD49b was assessed on liver NKp46^+^NK1.1^+^ populations, to identify ILC1 and NK cells respectively. CD3, CD19, Thy1, CD4, NKp46, NK1.1, CD49a, CD49b, KLRG1, RORγt, Gata3 and IL7Rα were assessed in SI to identify NK, ILC1, ILC2 and ILC3 populations of the lamina propria. Absolute numbers of indicated ILC populations in indicated organs; each symbol represents an individual mouse. The data shown are representative of two experiments with three mice for each condition. N.D.: None-detected. \* P=0.02 by Mann-Whitney test.](emss-69497-f005){#F5}

###### Distribution and cell counts of peripheral blood ILC subsets in healthy individuals

                          NK                ILC1            ILC2         ILC3                                                         
  ----------------------- ----------------- --------------- ------------ ----------------- ------------ ---------------- ------------ -----------------
  **Children (n = 29)**   8.3 (4.9-17.0)    215 (141-714)   30 (12-55)   1303 (387-3116)   32 (17-45)   1348 (88-3214)   34 (20-52)   1047 (380-3199)
  **Adults (n = 30)**     12.6 (6.4-24.6)   265 (98-514)    29 (15-63)   468 (249-1218)    31 (15-54)   585 (153-1566)   32 (18-52)   513 (180-2186)

Percentages and absolute counts of indicated ILC subsets in human peripheral blood of healthy children and adults are presented as medians (10th and 90th percentiles). Data were compiled from flow cytometry analysis performed as in [Fig. 1](#F1){ref-type="fig"}.

###### Clinical characteristics of patients

                                                           Color[a](#TFN2){ref-type="table-fn"}   Diagnosis[b](#TFN3){ref-type="table-fn"}   Samples post-HSCT   Age at HSCT (years)   Time interval between HSCT & ILC evaluation (years)   Donor origin[c](#TFN4){ref-type="table-fn"}   Conditionning regimen[d](#TFN5){ref-type="table-fn"}   T cell depletion[e](#TFN6){ref-type="table-fn"}   ATG (mg/kg)    Time interval between HSCT & last chimerism (years)   Last chimerism[f](#TFN7){ref-type="table-fn"}        
  -------------------------------------------------------- -------------------------------------- ------------------------------------------ ------------------- --------------------- ----------------------------------------------------- --------------------------------------------- ------------------------------------------------------ ------------------------------------------------- -------------- ----------------------------------------------------- ----------------------------------------------- ---- ----
  **Children with** ***JAK3*** **or** ***IL2RG* defect**                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  P1                                                       ![](emss-69497-i001.jpg)               γC                                         \+                  \+                    0.7                                                   12.8                                          MMRD                                                   0                                                 CD34_POS       0                                                     1.8                                             1    2
  P2                                                       ![](emss-69497-i002.jpg)               JAK3                                       \+                  \-                    0.6                                                   10.8                                          MMRD                                                   0                                                 CD34_POS       10                                                    0.7                                             1    3
  P3                                                       ![](emss-69497-i003.jpg)               γC                                         \+                  \+                    0.6                                                   10.6                                          MMRD                                                   0                                                 CD34_POS       10                                                    1                                               1    2
  P4                                                       ![](emss-69497-i004.jpg)               JAK3                                       \+                  \-                    0.4                                                   10.5                                          MMRD                                                   Bu 16 / Cy 200                                    CD34_POS       10                                                    10.5                                            1    1
  P5                                                       ![](emss-69497-i005.jpg)               γC                                         \+                  \+                    0.33                                                  10.4                                          MMRD                                                   0                                                 CD34_POS       5                                                     10                                              1    2
  P6                                                       ![](emss-69497-i006.jpg)               γC                                         \+                  \-                    0.75                                                  8.7                                           PRD                                                    0                                                 0              0                                                     ND                                              ND   ND
  P7                                                       ![](emss-69497-i007.jpg)               JAK3                                       \+                  \-                    0.6                                                   7.0                                           MSD                                                    0                                                 0              0                                                     2.4                                             1    2
  **Adults with** ***JAK3*** **or** ***IL2RG* defect**                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  P8                                                       ![](emss-69497-i008.jpg)               γC                                         \+                  \-                    0.1                                                   39.4                                          PRD                                                    0                                                 0              0                                                     27.8                                            1    2
  P9                                                       ![](emss-69497-i009.jpg)               JAK3                                       \+                  \-                    1.1                                                   30.3                                          MMRD                                                   Bu 8 / Cy 200                                     E-rosetting    10                                                    18.1                                            1    2
  P10                                                      ![](emss-69497-i010.jpg)               JAK3                                       \+                  \-                    0.8                                                   32.3                                          MMRD                                                   0                                                 E-rosetting    0                                                     8.6                                             1    2
  P11                                                      ![](emss-69497-i011.jpg)               JAK3                                       \+                  \+                    0.6                                                   29.7                                          PRD                                                    0                                                 0              0                                                     25                                              1    2
  P12                                                      ![](emss-69497-i012.jpg)               γC                                         \+                  \-                    0.6                                                   27.5                                          MMRD                                                   Bu 8 / Cy 200                                     In vitro mAb   0                                                     3.9                                             1    2
  P13                                                      ![](emss-69497-i013.jpg)               γC                                         \+                  \-                    0.15                                                  26.3                                          MMRD                                                   Bu 8 / Cy 200                                     In vitro mAb   0                                                     16.7                                            1    2
  P14                                                      ![](emss-69497-i014.jpg)               γC                                         \+                  \+                    0.5                                                   23.0                                          PRD                                                    0                                                                0                                                     11.0                                            1    2
  P15                                                      ![](emss-69497-i015.jpg)               γC                                         \+                  \+                    0.7                                                   22.2                                          MMRD                                                   Bu 8 / Cy 200                                     In vitro mAb   0                                                     9.9                                             1    2
  P16                                                      ![](emss-69497-i016.jpg)               γC                                         \+                  \+                    1.2                                                   20.1                                          MMRD                                                   0                                                 In vitro mAb   0                                                     8.9                                             1    2
  P17                                                      ![](emss-69497-i017.jpg)               γC                                         \+                  \-                    0.5                                                   21.4                                          MMRD                                                   Bu 8 / Cy 200                                     In vitro mAb   0                                                     2.3                                             1    2
  P18                                                      ![](emss-69497-i018.jpg)               γC                                         \+                  \-                    0.8                                                   17.4                                          MMRD                                                   0                                                 CD34_POS       0                                                     6.2                                             1    2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **CDC patients**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  C1                                                       ![](emss-69497-i019.jpg)               RAG-1                                      \+                  \-                    0.6                                                   8.5                                           UUCB                                                   Bu 12.8 / Cy 200                                  CD34_POS       7.5                                                   4.4                                             1    1
  C2                                                       ![](emss-69497-i020.jpg)               RAG-1                                      \+                  \-                    0.9                                                   10.5                                          MMRD                                                   Bu 16 / Cy 200                                    CD34_POS       10                                                    2                                               1    1
  C3                                                       ![](emss-69497-i021.jpg)               ALL                                        \+                  \-                    0.5                                                   4.4                                           UUCB                                                   Bu 12 / Cy 200                                    CD34_POS       7.5                                                   4.4                                             1    1
  C4                                                       ![](emss-69497-i022.jpg)               SAA                                        \+                  \-                    0.7                                                   5.2                                           MUD                                                    Flu 120 / Cy 200                                  CD34_POS       7.5                                                   6.4                                             1    1
  C5                                                       ![](emss-69497-i023.jpg)               ALL                                        \+                  \-                    6.5                                                   5.3                                           UUCB                                                   Flu 75 / Cy 120 / TBI                             CD34_POS       0                                                     4.7                                             1    1
  C6                                                       ![](emss-69497-i024.jpg)               AML                                        \+                  \-                    6.8                                                   13.5                                          MSD                                                    Bu 14 / Cy 200                                    CD34_POS       0                                                     11.7                                            1    1
  C7                                                       ![](emss-69497-i025.jpg)               ALL                                        \+                  \-                    5.4                                                   12.7                                          UUCB                                                   Cy 120 / TBI                                      CD34_POS       0                                                     12.5                                            1    1
  C8                                                       ![](emss-69497-i026.jpg)               SAA                                        \+                  \-                    9.5                                                   8.2                                           MSD                                                    Cy 200                                            CD34_POS       12.5                                                  8.3                                             1    1
  C9                                                       ND                                     RAG1                                       \-                  \+                    0.33                                                  ND                                            PRD                                                    0                                                 0              0                                                     ND                                              ND   ND
  C10                                                      ND                                     RAG2                                       \-                  \+                    0.55                                                  ND                                            MMRD                                                   Bu 12.8 / Cy 200                                  CD34_POS       10                                                    0.4                                             1    1
  C11                                                      ND                                     RAG1                                       \-                  \+                    0.33                                                  4.1                                           MMRD                                                   Bu 16 / Flu /TT                                   CD34_POS       10                                                    0.3                                             NA   1
  C13                                                      ND                                     RAG1                                       \-                  \+                    0.15                                                  ND                                            MMRD                                                   Bu 16 / Cy 200                                    CD34_POS       10                                                    0.2                                             NA   1

only patients for whom ILC evaluation has been performed post-graft

γc patients with mutations of the *IL2RG* gene; JAK3: patients with mutations of the *JAK3* gene; RAG1: patients with mutations of the *RAG1* gene; *RAG2*: patients with mutations of the *RAG2* gene, ALL: acute lymphoblastic leukemia; SAA: severe aplastic anemia; AML: acute myeloid leukemia.

MMRD: mismatched-related donor; PRD: pheno-related donor; UUCB: unrelated umbilical cord blood; MUD: matched unrelated donor; MSD : matched sibling donor

BU : busulfan (mg/kg total dose); Cy: cyclophosphamide (mg/kg total dose); Flu: fludarabine (mg/m^2^ total dose); TBI: total body irradiation.

CD34_pos : positive selection of CD34^+^ cells; mAb : negative selection by mAb

1= donor chimerism; 2= host myeloid chimerism; 3= mixed myeloid chimerism

ND: not done, NA: not applicable in absence of lymphocyte reconstitution at the time for chimerism evaluation

C12, P19, P20 and P21 are not indicated because peripheral blood ILC evaluations have been only performed before transplantation

###### Clinical follow up from 2 years post-HSCT until present

                                               Code [a](#TFN10){ref-type="table-fn"}   Iv Ig [a](#TFN10){ref-type="table-fn"}   Common warts   Severe HPV disease [b](#TFN11){ref-type="table-fn"}   E.N.T infections   Diarrhea                             Respiratory infection or disease   Other
  -------------------------------------------- --------------------------------------- ---------------------------------------- -------------- ----------------------------------------------------- ------------------ ------------------------------------ ---------------------------------- ----------------------------------------------------------------
  **Children with *JAK3* or *IL2RG* defect**                                                                                                                                                                                                                                                    
  P1                                           ![](emss-69497-i001.jpg)                1                                        0              0                                                     1                  1 [c](#TFN12){ref-type="table-fn"}   0                                  0
  P2                                           ![](emss-69497-i002.jpg)                0                                        0              0                                                     0                  0                                    0                                  0
  P3                                           ![](emss-69497-i003.jpg)                1                                        1              0                                                     0                  0                                    0                                  pancreatic insufficiency
  P4                                           ![](emss-69497-i004.jpg)                0                                        0              0                                                     0                  0                                    0                                  0
  P5                                           ![](emss-69497-i005.jpg)                1                                        0              0                                                     0                  1                                    0                                  hepatic granulomatous disease, IBD-like disease, onychomycosis
  P6                                           ![](emss-69497-i006.jpg)                0                                        1              1                                                     0                  0                                    0                                  0
  P7                                           ![](emss-69497-i007.jpg)                0                                        1              0                                                     0                  0                                    0                                  0
  **Adults with *JAK3* or *IL2RG* defect**                                                                                                                                                                                                                                                      
  P8                                           ![](emss-69497-i008.jpg)                1                                        0              0                                                     0                  0                                    0                                  0
  P9                                           ![](emss-69497-i009.jpg)                0                                        1              1                                                     0                  0                                    0                                  0
  P10                                          ![](emss-69497-i010.jpg)                0                                        0              0                                                     1                  0                                    0                                  0
  P11                                          ![](emss-69497-i011.jpg)                0                                        1              0                                                     0                  0                                    0                                  epilepsy
  P12                                          ![](emss-69497-i012.jpg)                1                                        0              0                                                     0                  0                                    1                                  0
  P13                                          ![](emss-69497-i013.jpg)                1                                        0              0                                                     0                  0                                    0                                  pheochromocytoma
  P14                                          ![](emss-69497-i014.jpg)                0                                        1              0                                                     0                  0                                    0                                  0
  P15                                          ![](emss-69497-i015.jpg)                1                                        0              0                                                     0                  0                                    0                                  0
  P16                                          ![](emss-69497-i016.jpg)                1                                        0              0                                                     0                  0                                    0                                  0
  P17                                          ![](emss-69497-i017.jpg)                0                                        1              0                                                     0                  0                                    0                                  0
  P18                                          ![](emss-69497-i018.jpg)                1                                        1              0                                                     1                  0                                    1                                  0
                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                
  **CDC patients**                                                                                                                                                                                                                                                                              
  C1                                           ![](emss-69497-i019.jpg)                0                                        0              0                                                     0                  0                                    0                                  0
  C2                                           ![](emss-69497-i020.jpg)                1 [d](#TFN13){ref-type="table-fn"}       0              0                                                     0                  0                                    0                                  0
  C3                                           ![](emss-69497-i021.jpg)                0                                        0              0                                                     0                  0                                    0                                  0
  C4                                           ![](emss-69497-i022.jpg)                0                                        0              0                                                     0                  0                                    0                                  0
  C5                                           ![](emss-69497-i023.jpg)                0                                        0              0                                                     0                  0                                    0                                  0
  C6                                           ![](emss-69497-i024.jpg)                0                                        0              0                                                     0                  0                                    0                                  0
  C7                                           ![](emss-69497-i025.jpg)                0                                        0              0                                                     0                  0                                    0                                  mediastinal lymphoma post HSCT
  C8                                           ![](emss-69497-i026.jpg)                0                                        0              0                                                     0                  0                                    0                                  0

immunoglobulin replacement

more than 30 cutaneous lesions during at least 2 years

inflammatory bowel-like disease improved after unconditioned T depleted boost performed 2 years after HSCT

absence of B cell reconstitution after anti CD20 monoclonal antibodies given for autoimmune hemolytic anemia

P19, P20 and P21 are not indicated because peripheral blood ILC evaluation have been only performed before transplantation

ND: not done
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